ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC). Issue 24 (1st November 2018)

• Record Type: Journal Article
• Authors: Morgensztern, Daniel; Cobo, Manuel; Ponce Aix, Santiago; Postmus, Pieter E.; Lewanski, Conrad R.; Bennouna, Jaafar; Fischer, Jürgen R.; Juan‐Vidal, Oscar; Stewart, David J.; Fasola, Gianpiero; Ardizzoni, Andrea; Bhore, Rafia; Wolfsteiner, Marianne; Talbot, Denis C.; Jin Ong, Teng; Govindan, Ramaswamy; on behalf of the ABOUND.2L+ Investigators,
• Is Part Of: Cancer. Volume 124:Issue 24(2018)
• Page Start: 4667
• Page End: 4675
• Publication Date: 2018-11-01
• Subjects: 5‐azacytidine -- advanced -- CC‐486 (oral 5‐azacitidine) -- nanoparticle albumin‐bound paclitaxel (nab‐paclitaxel) -- non‐small cell lung cancer (NSCLC) -- nonsquamous -- safety -- second‐line -- survival; Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.31779
• Languages: English
• ISSNs: 0008-543X

Abstract

Abstract : Background: This randomized phase 2 trial compared the efficacy and safety of second‐line nanoparticle albumin‐bound paclitaxel (nab‐paclitaxel) with or without the addition of CC‐486 (an oral formulation of 5‐azacytidine) in patients with advanced‐stage, nonsquamous non‐small cell lung cancer. Methods: Patients were randomized to receive either nab‐paclitaxel 100 mg/m 2 on days 8 and 15 plus CC‐486 200 mg daily on days 1 to 14 or single‐agent nab‐paclitaxel 100 mg/m 2 on days 1 and 8, with both regimens administered every 21 days until tumor progression or unacceptable toxicity. The primary endpoint was progression‐free survival. Secondary endpoints included the overall response rate, the disease control rate, and overall survival. Results: Between January 2015 and August 2016, 161 patients were randomized (81 to the combination arm and 80 to the single‐agent nab‐paclitaxel arm). There was no benefit from the addition of CC‐486 to nab‐paclitaxel. The median progression‐free survival was 3.2 months for the combination and 4.2 months for single‐agent nab‐paclitaxel (hazard ratio, 1.3; 95% confidence interval, 0.9‐1.9). The median overall survival was 8.1 months in the combination arm and 17 months in the single‐agent nab‐paclitaxel arms (hazard ratio, 1.7; 95% confidence interval, 1.08‐2.57). Grade 3 or greater treatment‐related, emergent adverse events were reported by 40.5% of patients in the combination arm and by 31.6% of those in the single‐agent nab‐paclitaxel arm. Conclusions: Single‐agent nab‐paclitaxel was associated with promising outcomes and a tolerable safety profile as second‐line treatment for patients with advanced‐stage, nonsquamous non‐small cell lung cancer. There was no benefit from the addition of CC‐486 to nab‐paclitaxel. Abstract : This randomized phase 2 trial compares the efficacy and safety of second‐line nanoparticle albumin‐bound (nab)‐paclitaxel with or without CC‐486, an oral formulation of 5‐azacytidine, in patients with advanced nonsquamous non‐small cell lung cancer. Single‐agent nab‐paclitaxel is associated with promising outcomes and has a tolerable safety profile, and no additional benefit is observed with the addition of CC‐486 to nab‐paclitaxel.